moderate - Elective cataract surgery volumes (primary DEXTENZA market) show modest correlation to consumer confidence and discretionary healthcare spending, as patients may defer procedures during economic uncertainty. However, Medicare coverage (65+ demographic) provides baseline demand stability. Pipeline indications targeting chronic diseases (wet AMD, DME) address medical necessity rather than elective procedures, reducing cyclical exposure. Overall sensitivity lower than consumer discretionary but higher than acute-care pharmaceuticals.

Rising interest rates create multiple headwinds: (1) Higher discount rates compress NPV of future pipeline cash flows, particularly punitive for pre-revenue assets 5-7 years from commercialization; (2) Increased cost of capital for future financing rounds given negative cash flow profile; (3) Biotech sector multiple compression as risk-free alternatives become more attractive. The company's 15.39x current ratio provides liquidity buffer, but eventual need for capital raises makes rate environment critical. Conversely, falling rates would support valuation expansion and cheaper financing access.

growth - The stock attracts speculative biotech investors focused on binary clinical/regulatory catalysts rather than current fundamentals. Negative earnings, minimal revenue base, and high volatility profile appeal to risk-tolerant growth investors betting on pipeline optionality. The -42% six-month return and -521% operating margin eliminate value and income investors. Momentum traders participate around data readouts and FDA decisions. Institutional ownership likely concentrated in healthcare-focused hedge funds and biotech specialists rather than broad index funds.